Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HBV resistant to lamivudine: experimental and clinical studies.

Hepatobiliary & pancreatic diseases international : HBPD INT - 1 Nov 2002

Zhou Dong-Yao, Cao Yong-Jian, Lin Lian-Ying, Wang Hong, Huang Jian-Sheng

Abstract excerpt

OBJECTIVE: To identify the impact of lamivudine on HBV e antigen (HBeAg) seroconversion and HBV DNA level, and the appearance of Tyr-Met-Asn-Asp (YMDD) resistants. METHODS: Forty-seven hepatitis B patients were treated with oral lamivudine. ALT level and HBeAg were detected in the treatment on the zero, 3rd, 6th and 9th month respectively. The levels of HBV DNA and YMDD resistants were analyzed with PCR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to DNA-Directed DNA Polymerase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Hepatitis Antibodies

Share to Hepatitis B

Share to Hepatitis B e Antigens

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 14607678

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HBV resistant to lamivudine: experimental and clinical studies.PMID 14607678Read ↗

[Distribution of lamivudine- resistant variants in hepatitis B virus].Semantic proximity Read ↗

Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.Semantic proximity Read ↗

[Clinical and virologic characteristics of lamivudine resistance in HBV-associated chronic liver disease].Semantic proximity Read ↗

Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.Semantic proximity Read ↗

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.Semantic proximity Read ↗

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.Semantic proximity Read ↗

Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China.Semantic proximity Read ↗

HBV mutations associated with lamivudine therapy.Semantic proximity Read ↗

Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.Semantic proximity Read ↗

Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains.Semantic proximity Read ↗

rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus.Semantic proximity Read ↗

Successful treatment of an entecavir-resistant hepatitis B virus variant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.